Posted inClinical Updates Wellness & Lifestyle
Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2: Clinical Advances and Therapeutic Implications
Phase 3 trials demonstrate that encapsulated cell therapy NT-501 significantly slows photoreceptor loss in MacTel, marking a promising disease-modifying approach with an acceptable safety profile.